Acquisition of securities by New Gen Holding company through contributions in kind and purchase of shares from minority financial shareholders of Generix Group (GENX – FR0010501692).
Paris the 13 June 2022 – Following the conclusion of an investment protocol on May 25, 2022 (the “ Protocol “), between Generix Group, its main managers, including Mr. Jean-Charles Deconninck, Mrs. Aïda Collette-Sène, Mr. Ludovic Luzza and Mr. Philippe Seguin (the ” Leaders ), Pléiade Investissement and its managers (“ Pleiade ”) and funds managed by Montefiore Investment (“ Montefiore “) announced by a previous press release dated the same day, the Directors, Pléiade and Montefiore announce that New Gen Holding has acquired, as of today, 2,977,942 Generix Group shares representing 13.1% of the capital (11.0 % on a fully diluted basis) and 12.7% of the voting rights of the latter with minority financial shareholders of Generix Group (the ” Acquisition “).
The Acquisition, carried out in accordance with the stipulations of the Protocol within the framework of the proposed filing of a public offer financed by Montefiore (the ” Public Offer “) (I’ ” Operation ”), was carried out by way of contributions in kind and disposals, at the rate of:
- 539,653 Generix Group shares, representing 2.38% of the capital (1.99% on a fully diluted basis) and 2.37% of the voting rights of the latter, acquired by way of contribution in kind by the partners of Pléiade to New Gen Holding; and
- 2,438,289 Generix Group shares, representing 10.74% of the capital (8.98% on a fully diluted basis) and 10.29% of the voting rights of the latter, acquired by sale by New Gen Holding from minority financial shareholders.
Pléiade, the Directors and Montefiore also entered into a shareholders’ agreement today providing in particular the rules governing their relations within New Gen as well as its governance, which will remain controlled exclusively by Pléiade until the closing of the Public Offer, and could be jointly controlled with Montefiore depending on the results of the Public Offer, in accordance with what was announced in previous press releases.
Following the Acquisition, the draft offer document in the context of the Public Offer will be filed before June 17th.
The parties will inform the market of the completion of these various stages.
EXT-FR-Generix-CP Closing 1_final
